Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07019558

Ophthalmological Disorders in Dominant Spinal-cerebellar Ataxias

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Spinocerebellar ataxias (SCA) are rare genetic neurological disorders. The most common forms are SCA1, SCA2 and SCA3. Another more recently identified cause of ataxia is SCA27B. These are progressive, incapacitating pathologies, with adult onset (generally between 30 and 60 years of age) and progressive involvement. They are characterized by gait instability (ataxia), coordination disorders (dysmetria) and speech disorders (dysarthria). A complex disorder may also be present, with impaired ocular motility, double vision (diplopia) and difficulties with eye movements (ophthalmoplegia). In clinical practice, investigators have observed patients with advanced forms of SCA1 or SCA3 reporting a progressive decline in visual acuity. Other recent scientific observations confirm the possible presence of additional ophthalmological damage to the retina or optic nerve in SCA1, SCA2 and SCA3 pathologies. This study is a cross-sectional study, including subjects with SCA1, SCA2 and SCA3 at different stages of the disease, including the presymptomatic stage, with a complete and systematic study of visual damage. The same study will be applied to subjects with SCA27B in order to study the presence or absence of visual impairment, and possibly compare it with those of patients with polyglutamine-expanded SCA.

Conditions

Interventions

TypeNameDescription
OTHERNeurological assessmentCollect retrospective and current clinical data and assess motor impairment
DIAGNOSTIC_TESTOphthalmological assessmentOphthalmological assessment of possible optic nerve or retinal damage.

Timeline

Start date
2025-10-10
Primary completion
2027-10-01
Completion
2027-10-01
First posted
2025-06-13
Last updated
2025-11-20

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT07019558. Inclusion in this directory is not an endorsement.